Related Experiment Video
Updated: Feb 13, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Clinical Trials and Progress in Metastatic Colon Cancer
Kabir Mody1, Tanios Bekaii-Saab2
1Gastrointestinal Cancer Program, Mayo Clinic Cancer Center, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Abstract:
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients-for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient-which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.
More Related Videos
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Statistical Software for Data Analysis and Clinical Trials
The Colonization of Land
Trial and Error and Algorithm